Search

Your search keyword '"Luisa Guidi"' showing total 231 results

Search Constraints

Start Over You searched for: Author "Luisa Guidi" Remove constraint Author: "Luisa Guidi"
231 results on '"Luisa Guidi"'

Search Results

1. Transition of inflammatory bowel disease patients from pediatric to adult care: an observational study on a joint-visits approach

2. Novel trends with biologics in inflammatory bowel disease: sequential and combined approaches

3. Magnesium Absorption in Intestinal Cells: Evidence of Cross-Talk between EGF and TRPM6 and Novel Implications for Cetuximab Therapy

4. Sustained Clinical Efficacy and Mucosal Healing of Thiopurine Maintenance Treatment in Ulcerative Colitis: A Real-Life Study

5. Harmful Effects and Potential Benefits of Anti-Tumor Necrosis Factor (TNF)-α on the Liver

6. Treatment of Crohn’s disease with colony-stimulating factors: An overview

7. Glucagon-like peptide-2 analogues for Crohn’s disease patients with short bowel syndrome and intestinal failure

9. Switching from IFX originator to biosimilar CT-P13 does not impact effectiveness,safety and immunogenicity in a large cohort of IBD patients

10. Incident Colorectal Cancer in Inflammatory Bowel Disease

11. I-CARE, a European Prospective Cohort Study Assessing Safety and Effectiveness of Biologics in Inflammatory Bowel Disease

12. Comparison of performances of infliximab biosimilars CT-P13 versus SB2 in the treatment of inflammatory bowel diseases: a real-life multicenter, observational study in Italy

13. Dual Targeted Therapy in Patient With Extensive Crohn's Disease: Different Response at Distinct Location

14. Predictors and Early Markers of Response to Biological Therapies in Inflammatory Bowel Diseases

15. Novel trends with biologics in inflammatory bowel disease: sequential and combined approaches

16. Novel trends with biologics in inflammatory bowel disease: sequential and combined approaches

17. Magnesium Absorption in Intestinal Cells: Evidence of Cross-Talk between EGF and TRPM6 and Novel Implications for Cetuximab Therapy

18. Impact of COVID-19 pandemic on the daily management of biotechnological therapy in inflammatory bowel disease patients: Reorganisational response in a high-volume Italian inflammatory bowel disease centre

19. TRPM7 Is Overexpressed in Human IBD-Related and Sporadic Colorectal Cancer and Correlates with Tumor Grade

20. Dual Targeted Therapy: a possible option for the management of refractory Inflammatory Bowel Disease

21. Mo1867 ITALIAN REAL-LIFE STUDY EVALUATING THE LONG TERM EFFECTIVENESS OF VEDOLIZUMAB FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE

22. TRPM7 Is Overexpressed in Human IBD-Related and Sporadic Colorectal Cancer and Correlates with Tumor Grade

23. Watery stools and metabolic acidosis

24. OC.02.5 EFFECTIVENESS, SAFETY AND IMMUNOGENICITY OF SWITCHING FROM ORIGINATOR INFILIXIMAB TO BIOSIMILAR INFLIXIMAB (CT-P13) IN A LARGE COHORT OF IBD PATIENTS

25. P106 Depressive symptoms and anxiety and their screening in IBD patients: performance of the distress thermometer in Italian IBD patients

26. Real-word incidence of inflammatory bowel disease among patients with other chronic inflammatory diseases treated with interleukin-17a or phosphodiesterase 4 inhibitors

27. Early vedolizumab trough levels predict treatment persistence over the first year in inflammatory bowel disease

28. Therapeutic drug monitoring with vedolizumab in inflammatory bowel disease

29. Cancer Risk in Inflammatory Bowel Disease: A 6-Year Prospective Multicenter Nested Case-Control IG-IBD Study

30. Use of biosimilars in inflammatory bowel disease: a position update of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD)

31. TREM1 predicts response to anti-tumor necrosis factor in inflammatory bowel diseases: Towards precision medicine

32. PROSIT Investigators. The PROSIT Cohort of Infliximab Biosimilar in IBD: A Prolonged Follow-up on the Effectiveness and Safety Across Italy

33. P321 Cessation of Anti-Tumour Necrosis Factor Therapy in Patients with Perianal Fistulizing Crohn’s Disease: Individual Patient Data Meta-Analysis of 323 patients from 12 studies

34. T04.01.16 VALIDITY AND APPLICABILITY OF HOSPITAL ANXIETY AND DEPRESSIONE SCALE (HADS) AND DISTRESS THERMOMETER (TD) IN INFLAMMATORY BOWEL DISEASES: AN ITALIAN MULTICENTER STUDY

35. Sa1825 ITALIAN REAL-LIFE STUDY EVALUATING THE LONG-TERM EFFECTIVENESS OF VEDOLIZUMAB FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE: THE ELDERLY COHORT

36. Sa1877 EFFECTIVENESS, SAFETY AND IMMUNOGENICITY OF SWITCHING FROM ORIGINATOR INFILIXIMAB TO BIOSIMILAR INFLIXIMAB (CT-P13) IN A LARGE COHORT OF IBD PATIENTS

37. Harmful Effects and Potential Benefits of Anti-Tumor Necrosis Factor (TNF)-α on the Liver

38. The PROSIT Cohort of Infliximab Biosimilar in IBD: A Prolonged Follow-up on the Effectiveness and Safety Across Italy

39. Therapeutic drug monitoring is more cost-effective than a clinically-based approach in the management of loss of response to infliximab in inflammatory bowel disease: an observational multi-centre study

40. OC.09.6 PERFORATING CROHN'S DISEASE AND EXTENSIVE COLITIS AS RISK FACTORS FOR INCIDENT CANCER: A MULTICENTER NESTED CASE-CONTROL IG-IBD STUDY AT 6 YEARS

41. OP0239 Histological features of joint and colonic inflammation in inflammatory bowel disease patients treated with anti-tnf

42. Patient and physician views on the quality of care for inflammatory bowel disease after one-year follow-up: Results from SOLUTION-2, a prospective IG-IBD study

43. Infliximab three-dose induction regimen in severe corticosteroid-refractory ulcerative colitis: Early and late outcome and predictors of colectomy

44. OC.12.3 INCIDENT CANCER IN INFLAMMATORY BOWEL DISEASE IN A PROSPECTIVE MULTICENTER NESTED CASE-CONTROL IG-IBD STUDY

45. OC.12.5 VEDOLIZUMAB TROUGH LEVELS AND CLINICAL OUTCOMES IN INFLAMMATORY BOWEL DISEASE

46. P802 Perforating Crohn's Disease and pancolitis as risk factors for incident cancer: a prospective multi-centre nested case–control IG-IBD study at 6 years

47. Achievement of sustained deep remission with adalimumab in a patient with both refractory ulcerative colitis and seronegative erosive rheumatoid arthritis

48. Prevalence and natural history of hepatitis B and C infections in a large population of IBD patients treated with anti-tumor necrosis factor-α agents

49. Anti TNF-α therapy for ulcerative colitis: current status and prospects for the future

50. Benefit-risk assessment of golimumab in the treatment of refractory ulcerative colitis

Catalog

Books, media, physical & digital resources